Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Fosun Kite's NDA Filing for CAR-T Therapy Accepted for China Review

publication date: Feb 25, 2020

Fosun Kite Biotechnology, a JV formed by Fosun Pharma and Kite Pharma of the US, announced its NDA for a CAR-T treatment has been accepted for review in China. Marketed in the US and EU as Yervoy, the CD19-directed CAR-T cell injection has completed a China bridging trial in adult patients with several forms of large B-cell lymphoma. The $95 million JV was formed three years ago to bring Kite's CAR-T product to China. The candidate is in line to be the first CAR-T product approved in China. More details....

Stock Symbol: (HK: 2196)

Share this with colleagues:

>



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital